Veeda Board appoints Dr Mahesh Bhalgat as Group CEO

Veeda Clinical Research announced the appointment of Dr Mahesh Bhalgat as the Group CEO. Dr Bhalgat has more than three decades of a successful career in developing business strategies, driving growth, spearheading multiple initiatives across several verticals, and managing operations in diverse businesses including, biopharma, vaccines, contract research, contract development and manufacturing, agricultural biotechnology, research reagents and services.

At Veeda, Dr Bhalgat will provide strategic leadership and drive the integration of different business segments to build a multinational integrated technology-enabled, clinical research organisation by overseeing a diverse portfolio of research services of Veeda group companies, which includes preclinical research business (Bioneeds India), and clinical research entity (Veeda Clinical Research).

Dr Bhalgat has vast experience of being in a senior leadership roles. Prior to joining Veeda, he was the COO for Syngene International (Biocon Group Company). Prior to that, he was the COO and Executive Director for Sanofi in Hyderabad, where he was responsible for initiating the manufacturing operation for injectable polio vaccine. He started his India career with Biological E, which he joined after 20 years in North America pursuing his study and working with multi-national drug development companies, which include Amgen and Monsanto and Thermofisher.